Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.18 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.69 million versus the consensus estimate of $7.53 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.